Pharmaceutical giants collectively embrace AI intelligent body: Bristol-Myers Squibb Company (BMY.US) promotes Claude to 30,000 employees.

Bristol-Myers Squibb Company (BMY.US) is promoting Anthropic's flagship Claude AI platform to its more than 30,000 employees in order to expand the application of artificial intelligence and AI intelligence in research, clinical development, and corporate operations. This collaboration marks a significant evolution for Bristol-Myers Squibb Company in deploying AI - it is moving beyond the conversational tools that defined the first wave of enterprise applications, and instead moving towards agency capabilities, integrating them into the daily workflows and systems that support its scientific research and global operations. Additionally, Bristol-Myers Squibb Company stated that it is using Anthropic's programming tool Claude Code to accelerate its software and AI development. The company also stated that it is currently evaluating the application of Claude AI agents in areas such as research, drug development, and commercial and medical affairs. Eric Kauder-Abrams, Head of Life Sciences at Anthropic, stated, "By empowering employees with the agency capabilities of Claude, which connects to thousands of internal company data sources, Bristol-Myers Squibb Company is building a single intelligent layer. This intelligent layer can generate clinical research reports from underlying experimental data, unearth the correct scientific background from decades of internal research, or identify the root causes of production deviations in real time." Anthropic's competitor OpenAI has also partnered with key players in the industry. OpenAI announced a partnership with biotech giant Moderna in 2024 to achieve business process automation, and earlier this year reached a deal with Novo Nordisk A/S Sponsored ADR Class B, the manufacturer of Wegovy, to accelerate drug development.